<DOC>
	<DOCNO>NCT02151240</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Foscarnet Sodium Sodium Chloride Injection patient herpes zoster , observe incidence Postherpetic neuralgia</brief_summary>
	<brief_title>Efficacy Safety Foscarnet Sodium Sodium Chloride Injection Patients With Herpes Zoster</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>1.Patients clinical diagnosis Herpes Zoster , able enrol study ≤ 72 hour appearance rash ; 2.1865 year old , men woman ; 3.VAS score≥4 ; 4.Patients n't receive antiviral medication enrollment ; 5.Patients able understand study procedure , agree participate give write consent . 1 . Patients history allergy Foscarnet Sodium Acyclovir ; 2 . Other combined infection ( bacteria , fungi ) 3 . Severe decline immune function , longterm use corticosteroid immunosuppressor 4 . Serious liver renal function abnormality ( Aspartate Transaminase ( AST ) alanine transaminase ( ALT ) ≥ 2.5x upper limit normal ( ULN ) , Creatinine ( Cr ) Blood urea nitrogen ( BUN ) ≥ 1x ULN ) 5 . Women pregnant lactating , woman childbearing potential fail use adequate method contraception avoid pregnancy ; 6 . Patients use antiviral drug ; 7 . Longterm use nonsteroid antiinflammatory drug , tricyclic antidepressant , antiepileptic drug analgesic 8 . Current malignant tumor ; 9 . Patients investigator consider inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>herpes zoster , Foscarnet Sodium , Acyclovir , Postherpetic neuralgia</keyword>
</DOC>